ArticleSignal transduction and targeted therapy2025
Molecular classification of hormone receptor-positive /HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies.
Abstract read
In one paragraph
Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- De-Escalation of Neoadjuvant Treatment for HER2-Positive Breast Cancer.International journal of cancer · 2026Review
- Insights into the Complexities of Pharmacotherapy Parameters in Artificial Intelligence Models for Drug Selection, Precision Personalised Medicine and Optimal Therapeutic Outcomes.Pharmaceutics · 2026Review
- Impact of Trastuzumab and Pertuzumab on HER2 Localization and the Estrogen Receptor Cistrome in ER+/HER2+ Breast Cancer.bioRxiv : the preprint server for biology · 2026Article
- Article
- In situ imaging of proximal biomolecules via Proximity Anchored Modules Assembly.Journal of nanobiotechnology · 2026Article
- Dynamic Evolution of HER2 Expression Following Neoadjuvant Therapy and Its Association With Treatment Response and Prognosis in Breast Cancer: A Large-Scale Retrospective Study.World journal of surgery · 2026Article
- Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk.Journal of translational medicine · 2026Review
- Decoding the gut microbiota metabolite-matrix metalloproteinase-3 axis in breast cancer: a multi-omics and network pharmacology study.Molecular diversity · 2026Article
- Focused ultrasound for cellular mechanoactivation and nanomedicine delivery in cancer.Biomedical microdevices · 2026Review
- Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors.Journal of personalized medicine · 2026Review
- Association of Post-Neoadjuvant Chemotherapy MRI andDiagnostics (Basel, Switzerland) · 2026Article
- MicroRNA-mediated modulation of cancer-associated fibroblasts in HER2-positive breast tumor microenvironment: a comprehensive review.Discover oncology · 2026Review
- Organoids for disease modeling and treatment: state-of-the-art.Experimental hematology & oncology · 2026Review
- A fusion-deletion genomic-event underlies poor prognosis in young patients with luminal breast cancer.PloS one · 2026Article
- An updated review on the role of extracellular vesicles in immune system modulation in breast cancer with special emphasis on immune checkpoint regulators.Frontiers in immunology · 2026Review
- Review
- Efficacy and safety of pyrotinib combined with trastuzumab and chemotherapy in patients with HER2-positive locally advanced breast cancer: a multicenter real-world study.American journal of translational research · 2026Article
- Organoids glimpse: the nexus for diverse tumor heterogeneity.Frontiers in cell and developmental biology · 2026Review
- Cholesterol metabolism and cancer: Molecular mechanisms, immune regulation and an epidemiological perspective (Review).International journal of molecular medicine · 2025Review
- From mechanism to application: programmed cell death pathways in nanomedicine-driven cancer therapies.Bioactive materials · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Chao Liu *Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China.
Lisha Sun *Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China.
Nan Niu *Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China.
Pengjie Hou *Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China.
Guanglei Chen *Cancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China.
Hao WangCancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China.
Zhan ZhangCancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China.
Xiaofan JiangCancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China.
Qianshi XuCancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China.
Yafei ZhaoCancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China.
Yimin WangCancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China.
Yuan ShiDepartment of Breast Surgery, Anyang Tumor Hospital, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China.
Mingxin LiuCancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China.
Yongliang YangShanghai General Medical Center, School of Clinical Medicine, Shanghai University of Medicine & Health Science, Shanghai, China.
Wei QianCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China.
Jiandong WangDepartment of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing, China. vicky1968@163.com.
Caigang LiuCancer Stem Cell and Translation Medicine Lab, Shengjing Hospital of China Medical University, Shenyang, China. liucg@sj-hospital.org.ORCID 0000-0003-2083-235X
Funding
National Natural Science Foundation of China (National Science Foundation of China) No.82203804National Natural Science Foundation of China (National Science Foundation of China) No.82403918National Natural Science Foundation of China (National Science Foundation of China) No. U20A20381
Abstract
Significant heterogeneity exists in hormone receptor (HR)-positive/HER2-positive (HR
Indexed as
Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyReceptors, EstrogenFemaleHumansMiddle AgedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, Estrogen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.